Based on the key indicators related to Phathom Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Phathom Pharmaceuticals may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At this time, Phathom Pharmaceuticals' Other Assets are comparatively stable compared to the past year. Capital Lease Obligations is likely to gain to about 1.6 M in 2025, despite the fact that Total Stockholder Equity is likely to grow to (62.2 M). Key indicators impacting Phathom Pharmaceuticals' financial strength include:
The essential information of the day-to-day investment outlook for Phathom Pharmaceuticals includes many different criteria found on its balance sheet. An individual investor should monitor Phathom Pharmaceuticals' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Phathom Pharmaceuticals.
Please note, the imprecision that can be found in Phathom Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Phathom Pharmaceuticals. Check Phathom Pharmaceuticals' Beneish M Score to see the likelihood of Phathom Pharmaceuticals' management manipulating its earnings.
Phathom Pharmaceuticals Stock Summary
Phathom Pharmaceuticals competes with Day One, Blueprint Medicines, Lyra Therapeutics, Cullinan Oncology, and Acumen Pharmaceuticals. Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey. Phathom Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 77 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
Phathom Pharmaceuticals Key Income Statement Accounts
The reason investors look at the income statement is to determine what Phathom Pharmaceuticals' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Phathom Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Phathom Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Phathom Pharmaceuticals competition to find correlations between indicators driving Phathom Pharmaceuticals's intrinsic value. More Info.
Phathom Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, Phathom Pharmaceuticals' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Phathom Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Phathom Pharmaceuticals Systematic Risk
Phathom Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Phathom Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-one with a total number of output elements of fourty. The Beta measures systematic risk based on how returns on Phathom Pharmaceuticals correlated with the market. If Beta is less than 0 Phathom Pharmaceuticals generally moves in the opposite direction as compared to the market. If Phathom Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Phathom Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Phathom Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Phathom Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Phathom Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Phathom Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Phathom Pharmaceuticals growth as a starting point in their analysis.
Price Earnings To Growth Ratio
0.0817
At this time, Phathom Pharmaceuticals' Price Earnings To Growth Ratio is comparatively stable compared to the past year.
Phathom Pharmaceuticals February 18, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Phathom Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Phathom Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Phathom Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Phathom Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Phathom Pharmaceuticals's daily price indicators and compare them against related drivers.
When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.